Selective FGFR inhibitor (HMPL-453)

 

HMPL-453 is a novel, small molecule, selective FGFR inhibitor. HMPL-453 is being developed for the treatment of cancers such as small cell lung cancer, breast cancer, multiple myeloma, gastric cancer and bladder cancer. Presently it is in pre-clinical stage.  Preliminary study results indicated that HMPL-453 was well tolerated in cancer patients and exhibited a favourable pharmacokinetic profile.

Related Links